Stockscreener 앱 받기
63.38
0.14%
0.2243
전일 마감가:
$63.60
열려 있는:
$64.08
하루 거래량:
1.60M
Relative Volume:
0.15
시가총액:
$129.59B
수익:
$48.48B
순이익/손실:
$7.27B
주가수익비율:
17.79
EPS:
3.5626
순현금흐름:
$11.91B
1주 성능:
-0.10%
1개월 성능:
-1.46%
6개월 성능:
+6.66%
1년 성능:
+38.00%
1일 변동 폭
$63.17
$64.35
1주일 범위
$63.15
$65.29
52주 변동 폭
$42.52
$68.64
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
63.44 | 130.00B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,144.89 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
268.90 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.32 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
146.32 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
140.88 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Baird Financial Group Inc. Cuts Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Why is Bristol Myers Squibb (NYSE:BMY) stock in focus today? - Kalkine Media
Bristol Myers Squibb (BMY) Faces Fresh Patent Pressure In Cardiac Drug Fight - simplywall.st
Bristol Myers Squibb awarded honour for being first employer to gain triple-region Menopause Friendly Accreditation - hrnews.co.uk
Bristol-Myers Squibb stock heads into the open after a 1.0 percent dip - ad-hoc-news.de
Bristol-Myers Squibb Co (BMY) Insider Sale: EVP, Chief Medical O - GuruFocus
Multiple Myeloma Market Poised for Sustained Growth Amid Advancements in Treatment and Clinical Innovation by 2036 – DelveInsight | Regeneron, Sanofi, Arcellx, Gilead, AbbVie, Bristol-Myers Squibb - Barchart.com
BMY Gains 19.4% Year to Date: Should You Buy, Sell or Hold the Stock? - TradingView
Core Capital Management & Research inc. Invests $4.73 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Passes the Dividend Screen, but Payout Sustainability Is the Key Question - ChartMill
Allworth Financial LP Sells 91,375 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb stock heads into the open after a 3.2 percent drop - ad-hoc-news.de
Bristol-Myers Squibb stock heads into the open after a 3.2 percent drop - ad-hoc-news.de
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion? - Zacks Investment Research
What macro factors could move Bristol Myers Squibb (NYSE:BMY) shares this week? - Kalkine Media
National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort - Finviz
Bristol Myers Squibb Company $BMY Shares Purchased by Waverly Advisors LLC - MarketBeat
CD&R Taps Former Bristol-Myers CEO Caforio in Healthcare Push - Bloomberg.com
Bristol Myers (NYSE: BMY) insider unloads 6,249 shares - Stock Titan
Bristol-Myers Squibb stock heads into the open after a 3.2% drop - ad-hoc-news.de
Bristol-Myers Squibb Co (BMY) Shares Fall 3.2% -- What GF Score of 71 Tells Investors - GuruFocus
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.25% on Sep 8: Facts Behind the Movement - TradingKey
Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial | Business Information & News | FE - Westlaw Today
What's Going On With Bristol Myers Stock Today?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol Myers Squibb stock gains on positive arlocabtagene autoleucel trial results - AD HOC NEWS
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy - Yahoo Finance
Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial - Reuters
Bristol Myers' blood cancer cell therapy meets main goal in mid-stage trial - yahoo.com
Why Is Bristol Myers Squibb (NYSE:BMY) Under NYSE Focus Today? - Kalkine Media
Bristol Myers Squibb Company $BMY Shares Acquired by Amundi - MarketBeat
Bristol Myers Squibb stock heads into the open after a 1.9% slide - ad-hoc-news.de
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
VIRGINIA RETIREMENT SYSTEMS ET Al Takes $99.23 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb (BMY): Investor Outlook with a Focus on Dividend Yield and Strategic Collaborations - DirectorsTalk Interviews
TD Waterhouse Canada Inc. Buys 53,881 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Why Davy thinks Bristol-Myers Squibb’s latest rally is one to cash in on - Business Post
Saudi Central Bank Purchases 67,780 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Mid American Wealth Advisory Group Inc. - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup - ChartMill
Munich Reinsurance Co Stock Corp in Munich Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by NEOS Investment Management LLC - MarketBeat
Bristol Myers Squibb Company $BMY Position Boosted by Concurrent Investment Advisors LLC - MarketBeat
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today - Yahoo Finance
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Will Long‑Term Camzyos Data and Real‑World Evidence Change Bristol Myers Squibb's (BMY) Narrative? - simplywall.st
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? - TradingView
Bristol-Myers Squibb stock steadies as CAR-T trial pause meets strong Q2 2026 figures - AD HOC NEWS
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths - Benzinga
Bristol Myers Squibb: Still Cheap, Despite What The Chart Says (NYSE:BMY) - Seeking Alpha
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.89%
자본화:
|
볼륨(24시간):